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Abstract
Objectives: Investigating factors that contribute to bone loss and accretion
across populations in remote settings is challenging, particularly where diag-
nostic tools are scarce. To mitigate this challenge, we describe validation of a
commercial ELISA assay to measure osteocalcin, a biomarker of bone forma-
tion, from dried blood spots (DBS).
Methods: We validated the Osteocalcin Human SimpleStep ELISA kit from
Abcam (ab1951214) using 158 matched plasma and DBS samples. Passing-
Bablok regression analysis assessed the relationships between plasma and DBS
osteocalcin concentrations. Dilutional linearity and spike and recovery experi-
ments determined if the DBS matrix interfered with osteocalcin measurement,
and intra- and inter-assay coefficients of variation (CVs) were calculated. Limit
of detection, analyte stability, and specific forms of osteocalcin measured by
the kit were also investigated.
Results:Meanplasmaosteocalcin valuewas 218.2 ng/mL (range 64.6-618.1 ng/mL).
Linear relationships existed between plasma and DBS concentrations of
osteocalcin, with no apparent bias in plasma vs DBS concentrations. There
was no apparent interference of the DBS matrix with measurement of
osteocalcin in DBS. Intra-assay CV for DBS was ~8%, while average inter-assay
CV was 14.8%. Limit of detection was 0.34 ng/mL. Osteocalcin concentrations
were stable in DBS stored at−28C and room temperature, but not those stored
at 37C. This ELISA kit detects total osteocalcin.
Conclusions: Osteocalcin, a bone formation biomarker, can be measured
from DBS. Combined with a previously validated DBS assay for TRACP-5b, a
bone resorption biomarker, these assays have the potential to help researchers
disentangle the many factors contributing to bone strength.
1 | INTRODUCTION
Bone is a highly vascularized, metabolically active, and
dynamic organ that undergoes processes of formation
and resorption throughout the lifespan. This remodeling
ability involves the resorption of older microdamaged
bone by osteoclasts and deposition of new bone tissue by
osteoblasts. During typical subadult growth, bone forma-
tion outpaces resorption whereas throughout adulthood
and particularly during skeletal aging, disproportionately
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greater osteoclast activity relative to osteoblast activity
may occur, contributing to compromised bone mineral
density (BMD; grams of mineral per area or volume) and
bone quality (a collective term that includes micro-
architecture, bone turnover, damage accumulation, and
mineralization) (Bartl & Frisch, 2009; Grynpas, 2003).
Severely compromised bone strength, due to low BMD
and microarchitectural deterioration of bone tissue, may
be clinically defined as osteoporosis (Kanis et al., 2008;
Singh, Kumar, & Lal, 2015), a debilitating, systemic con-
dition associated with increased risk of fractures, disabil-
ity, and chronic pain (Siris et al., 2014).
Many endogenous and exogenous factors contribute to
bone quality and thus bone strength, including those widely
recognized in chronic disease etiology more broadly: nutri-
tion, hormonal status, physical activity level, genetics, and
reproductive patterns, to name a few (Madimenos, 2015).
For anthropologists investigating how heterogeneous eco-
logical conditions shape human variability in bone accretion
and loss within developmental stages across the life course,
unraveling the complex interaction of influencing factors is
a critical, albeit daunting task (Agarwal & Glencross, 2010;
Madimenos, Liebert, Cepon-Robins, Snodgrass, & Sugi-
yama, 2015). Furthermore, for field researchers working
with small-scale, remote populations, high cost, and infra-
structural limitations preclude the availability of “gold-stan-
dard” bone imaging instruments like dual-energy x-ray
absorptiometry (DEXA) that would otherwise be preferable
for addressing these research questions. This lack of access
largely explains the paucity of data available from non-
industrialized, non-Western populations, although this
is starting to be remedied. Portable quantitative ultra-
sound devices have facilitated research into the effects
of developmental and lifestyle factors on BMD, specifi-
cally among subsistence-based populations like the
Shuar forager-horticulturalists of Amazonian Ecuador
(Madimenos, Snodgrass, Liebert, Cepon, & Sugiyama, 2012),
rural nonindigenous Colonos of Ecuador (Madimenos
et al., 2011; Madimenos et al., 2012), and the forager-
horticulturalist Tsimane of Bolivia (Stieglitz et al.,
2015; Stieglitz, Trumble, Kaplan, & Gurven, 2017).
Despite the insights these studies have provided
(Madimenos et al., 2020), BMD is simply one surrogate mea-
sure of bone strength and moreover, reflects the combined
contributions of formation and resorption processes. Dis-
entangling these distinct processes outside clinical settings is
invaluable for enhancing current understanding of the rela-
tive contributions and interactions of life-stage and lifestyle
factors to bone health more broadly (Agarwal &
Glencross, 2010).
Measures of bone resorption and formation (ie, bone
turnover) through biomarker analyses offer an opportunity
to extricate the processes contributing to bone strength.
Serum biomarkers of bone resorption include collagen
degradation products such as hydroxyproline, cross-linked
telopeptides of type I collagen, and osteoclast enzymes
such as tartrate-resistant acid phosphatase 5b (TRACP-5b).
Total alkaline phosphatase, bone alkaline phosphatase, and
osteocalcin are protein biomarkers that have been used as
markers of bone formation (Eastell & Hannon, 2008).
Recently, we validated a dried blood spot (DBS)-based assay
of one marker of bone resorption, namely TRACP-5b (Eick
et al., 2019); however, until now, no validated assay for
measuring a marker of bone formation in DBS samples has
been reported. Because DBS assays facilitate measurement
of biomarkers from populations in remote, field-based set-
tings often characterized by limited diagnostic equipment,
the development of such an assay has both clinical and non-
clinical (eg, anthropological) value.
Osteocalcin, which is synthesized by osteoblasts,
odontoblasts, and hypertrophic chondrocytes, is the
major noncollagenous protein found in the bone matrix
(Kuo & Chen, 2017); circulating osteocalcin represents
the total fraction of osteocalcin not bound to the hydroxy-
apatite matrix of bone. Intact osteocalcin is a 49 amino
acid molecule with three glutamic acid residues (amino
acid positions 17, 21, 24) that can be carboxylated by
γ-glutayml carboxylase using vitamin K as a co-factor.
Osteocalcin, with all three of the glutamic acid residues
carboxylated, is referred to as carboxylated osteocalcin
(cOC), vs the uncarboxylated (no γ-carboxyglutamic acid
residues) or undercarboxylated forms (1 or 2 γ-
carboxyglutamic acid residues). Total osteocalcin (tOC) is
the sum of the carboxylated and uncarboxylated forms of
osteocalcin (Lee, Hodges, & Eastell, 2000). The carboxyl-
ated form of osteocalcin has a high affinity for calcium
and hydroxyapatite, and this is the major form involved
in bone formation. In contrast, the uncarboxylated and
undercarboxylated forms appear to act as hormones
involved in glucose metabolism (Booth, Centi, Smith, &
Gundberg, 2013; Zoch, Clemens, & Riddle, 2016). Serum
concentrations of tOC are generally proportional to osteo-
blast activity, and thus, tOC is an established proxy mea-
sure of bone formation (Booth et al., 2013; Zoch
et al., 2016).
In addition to variation in the extent of carboxylation
of osteocalcin, five different fragments of osteocalcin may
be circulating in addition to the intact fragment: an N-
terminal fragment (aa 1-19), mid fragment (aa 20-43),
and C-terminal fragment (aa 44-49), as well as an N-
terminal mid form (aa 1-43) and a mid-C terminal form
(aa 20-49). The intact 49-aa molecule and N-terminal mid
fragment are the most abundant circulating forms
(Garnero, Grimaux, Seguin, & Delmas, 1994), and are the
forms targeted by most currently available osteocalcin
ELISA assays.
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Clinically, osteocalcin levels are used to monitor bone
turnover in metabolic diseases such as osteoporosis and
growth hormone deficiency (Brown et al., 1984; Lee
et al., 2000). High serum osteocalcin levels are a marker
of either rapid bone formation, as seen in adolescence,
or increased bone turnover, which results in a decrease
in mineralization and therefore binding substrate for
osteocalcin, as seen in osteoporosis (Boivin, Chavassieux,
Santora, Yates, & Meunier, 2000; Szulc & Bauer, 2013).
Low osteocalcin levels are associated with decreased bone
turnover (Brown et al., 1984; Szulc & Bauer, 2013). In
clinical practice, osteocalcin levels are measured in
serum obtained from venous blood draws; however,
while collection and processing of venous blood is feasi-
ble under some field circumstances (Gurven et al., 2017),
the logistical, shipping, and biosafety advantages as well
as low cost and analyte stability afforded by use of DBS
have made them the biosampling method of choice for
many biological anthropologists working with remote or
underserved populations.
DBS cards are created by collecting a small amount
(40-60 μL) of fingerprick blood on filter paper cards spe-
cifically manufactured for this purpose. After collection
of blood drops, the cards are allowed to air-dry for 3 to
4 hours, and can then be packaged in a resealable storage
bag with desiccant packets. It may then be possible to
ship the DBS samples to their destination at ambient
temperatures, as some biomarkers have been found to be
very stable in DBS. Alternatively, the samples can be fro-
zen for less stable biomarkers. When frozen at −20C to
−80C in frost-free freezers, they can remain viable for
years, although there is variability across different bio-
markers of interest.
Here we describe the systematic validation of a com-
mercially available ELISA to measure levels of osteocalcin
in DBS.
2 | METHODS
2.1 | ELISA kit
We validated Abcam's Osteocalcin Human SimpleStep
ELISA kit for use with DBS (ab195214). This ELISA kit
detects intact osteocalcin and was developed for quanti-
tative measurement of osteocalcin in human serum,
plasma, and serum-free cell culture supernatants. The
manufacturer-reported sensitivity of this kit is 0.1 ng/mL
with a measurement range of 0.16 to 10 ng/mL
osteocalcin. Preliminary experiments revealed that a
single 3-mm diameter punch from a DBS eluted in
100 μL of diluent provided with the kit provided suffi-
cient signal (data not shown).
2.2 | Validation samples
One hundred fifty-eight matched fingerprick DBS
(fDBS), venous blood DBS (vDBS), and plasma samples
collected from a convenience sample of adults in
Eugene/Springfield, Oregon between November 2014
and February 2015 were used to validate the osteocalcin
ELISA following an established protocol (Eick, Kowal,
Barrett, Thiele, & Snodgrass, 2017). Ninety-one partici-
pants were female, with an age range of 18 to 72 years,
median age of 26 years, and average age of 31.6 years. Age
range of the 67 male participants was 18 to 80 years,
median age was 28 years, and mean age was 31.6 years,
indicating no major skew in age between male and female
participants. All samples were collected between 5 PM and
9 PM in the evening. This collection was approved by the
Committee for the Protection of Human Subjects, Univer-
sity of Oregon (#7062016.007) and all participants pro-
vided informed consent.
2.3 | Measurement of osteocalcin in
E2V2 samples
Osteocalcin level was assessed in 158 plasma samples
stored at −80C (M:F 67:91). Plasma samples were diluted
1/100. A histogram was plotted of these plasma concentra-
tions using Graphpad Prism software. Osteocalcin concen-
tration ranged from 64.6 to 69.1 ng/mL in these
158 samples, with a median value of 196.6 ng/mL and
mean value of 218.2 ng/mL. Fifty individuals with plasma
osteocalcin values spanning the range of concentrations
measured in the 158 samples (64.6-619.1 ng/mL) were
identified. Levels of osteocalcin were then measured in
matched fDBS and vDBS samples from these 50 individuals
(M:F 16:34).
2.4 | Plasma/DBS comparisons
To assess if plasma, fDBS, and vDBS osteocalcin values
were normally distributed, the D'Agostino and Pearson
omnibus normality test was used. While the fDBS and
vDBS values were normally distributed, the plasma values
were not, therefore Passing-Bablok and Bland-Altman com-
parisons were done after log10 transforming the osteocalcin
values, as this normalized the distributions of all osteocalcin
values. Passing-Bablok regression analysis was used to
assess relationships between osteocalcin values of the
matched samples, as this analysis assumes uncertainty
in both sets of values being compared. Bias was evalu-
ated by Bland-Altman analyses (Bland & Altman, 1986).
DBS values were converted into plasma-equivalent
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values using the Passing-Bablok regression equations, as
DBS dilution values cannot be determined (amount of
plasma in one 3-mm punch will differ from sample to
sample depending on the hematocrit and size of the
dried blood spot in addition to location of DBS from
which the spot was punched). The difference between
plasma-equivalent fDBS or vDBS values and plasma
values was plotted against the average of these values,
and Bland-Altman plots were examined for bias and the
number of samples that fell outside the 95% confidence
intervals.
2.5 | Linearity of dilution
To assess the dilutional linearity of this assay for DBS
samples, six vDBS samples with high osteocalcin concen-
trations were serially diluted 1:2, 1:4, 1:8, and 1:16 and
the values obtained for the diluted samples (multiplied
by the dilution factor) were compared to those measured
for the undiluted sample.
2.6 | Spike and recovery
To assess if the DBS sample matrix contained any factors
that interfere with detection of osteocalcin levels, we per-
formed a spike and recovery experiment using two DBS
samples with low intrinsic osteocalcin concentrations. In
more detail, six punches from vDBS samples of two indi-
viduals were eluted in 700 μL assay buffer, and then the
same volume of diluted osteocalcin standard provided
with the ELISA kit was added to three 150 μL aliquots of
eluted sample to achieve final osteocalcin concentrations
of 5, 2.5, and 1.25 ng/mL. Sample diluent tubes with the
same amounts of osteocalcin added as were added to the
DBS eluates served as comparators to assess percentage
recovery.
2.7 | Precision: Intra- and inter-assay
coefficients of variation
To determine intra-assay variation, duplicate punches
from all 50 vDBS and 50 fDBS samples were each eluted
in 100 μL sample diluent, 50 μL of each duplicate eluate
was loaded in a well, and then the coefficient of variation
(CV) for each duplicate set of wells was calculated. To
calculate inter-assay variation, two duplicate punches
from a high osteocalcin vDBS sample and low osteocalcin
vDBS sample were run on each plate (n = 6) and the
coefficient of variation of the mean value of the high and
low controls on each plate was calculated.
2.8 | Limit of detection
The limit of detection of the assay in our laboratory was
determined by calculating the mean of 28 wells containing
the zero standards (assay buffer only), adding two SD to this
value, and then extrapolating the corresponding concentra-
tion of this from the four-parameter logistic curve for that
plate.
2.9 | Analyte stability
Separate 3-mm punches taken from six vDBS samples from
different individuals were stored at −28C, room tempera-
ture, and 37C for 2, 7, 14, and 28 days to determine the sta-
bility of osteocalcin concentrations to various storage
conditions. Osteocalcin levels in these samples were
expressed as a percentage of the osteocalcin concentration in
matched samples stored at −80C that were thawed only for
this assay. To assess the impact of the number of freeze-thaw
cycles on osteocalcin concentrations, vDBS samples from the
same six individuals were allowed to thaw at room tempera-
ture for 2 hours 2, 4, 8, or 12 times and were refrozen after
each thawing session at −28C. All samples were thawed a
final time for the assay for a total number of freeze-thaw
cycles of 3, 5, 9, and 13, respectively. Osteocalcin levels in
these samples were expressed as a percentage of the
osteocalcin concentration in matched samples stored at
−80C that were thawed only once.
2.10 | Form of osteocalcin measured
To assess the specificity of the ELISA kit for carboxylated
osteocalcin (cOC), we diluted cOC from Anaspec (cat. #
AS-22829; [Gla17,21,24]-Osteocalcin (1-49)) to the same
concentrations as used for the osteocalcin standard pro-
vided with the kit. If the antibodies used in the kit were spe-
cific for cOC, we expected the values obtained for the
Anaspec dilutions to be roughly similar to those of the stan-
dard. Lower values for the Anaspec standard dilutions than
the kit standard dilutions would indicate that the antibodies
provided with the kit detect both carboxylated and un(der)
carboxylated forms of osteocalcin, that is, total osteocalcin.
3 | RESULTS
3.1 | Measurement of osteocalcin in
E2V2 samples
Among 158 individuals for whom plasma osteocalcin
values were measured, the mean plasma osteocalcin
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concentration was 218.2 ng/mL, the median osteocalcin
concentration was 196.6 ng/mL, and osteocalcin values
ranged from 64.6 to 619.1 ng/mL. Osteocalcin plasma values
were not significantly different between males and females
(MannWhitneyU test, P= .06, two-tailed). Due to the tempo-
rary increase in osteocalcin levels documented among females
in their sixth decade and the generally higher osteocalcin
values in postmenopausal women (Vanderschueren, Gevers,
Raymaekers, Devos, & Dequeker, 1990), an additional analy-
sis excluded females ≥50 years. In a comparison of males vs
females <50 years, osteocalcin values were significantly
higher inmales (MannWhitneyU test, P= .02, two-tailed). In
addition, osteocalcin plasma values were negatively correlated
with age in males (n = 67, Spearman's correlation coeffi-
cient =−0.55, P < .01) but not in females (n = 91, Spearman's
correlation coefficient = −0.15, P= .16). However, when only
females <50 years were analyzed, osteocalcin levels were sig-
nificantly inversely related to age (n = 79, Spearman's correla-
tion coefficient =−0.34, P < .01). fDBS values (n = 50) ranged
from 0.43 to 6.03 ng/mL, with mean and median values of
2.53 and 2.49 ng/mL, respectively. Venous DBS (vDBS) values
(n = 49 after excluding one sample with an osteocalcin con-
centration below the limit of detection of the assay) had
osteocalcin values ranging from 0.36 to 4.25 ng/mL, with
mean andmedian values of 1.92 and 1.85, respectively.
3.2 | Plasma/DBS comparisons
There was a linear relationship between all pairwise com-
parisons of matched sample types (Figure 1; Passing Bab-
lok regression equations reported on each graph). There
was no obvious pattern of bias for the fDBS and vDBS
vs plasma comparisons (Figure 2A,B), indicating that
plasma osteocalcin levels are not systematically different
from fingerprick osteocalcin values. There did appear to
be a bias in the plot of fDBS vs vDBS values, with fDBS
values generally higher than those of the matched vDBS
sample (Figure 2C). However, when the vDBS and fDBS
values were converted to their plasma-equivalent values
and compared, no obvious bias was observed in the
Bland-Altman plot (Figure 2D). It is unclear what to attri-
bute the higher fDBS than vDBS values to; we previously
observed slightly higher levels of TRACP-5b in vDBS
than fDBS, and attributed this to the generally smaller
diameters of the fDBS than vDBS and correspondingly
lower analyte concentrations (Eick et al., 2017; George &
Moat, 2016), but we observed the opposite pattern here.
3.3 | Linearity of dilution
Dilutional linearity results are presented in Table 1. None of
the 1:16 dilution values is shown as these were below the
limit of detection of the assay, while two of the 1:8 diluted
samples also had values below the limits of detection.
Recovery ranged from 85.6% to 116.3%, with an average
recovery of 99.3%, indicating dilutional linearity of this assay
for DBS in the dilution range of 1:2 to 1:4, and possibly as
high as 1:8 in some participants with higher concentrations.
3.4 | Spike and recovery
Recovery values after spiking ranged from 96% to 102%
(Table 2), indicating excellent recovery of osteocalcin in
the sample and the absence of interfering factors.
3.5 | Precision: Intra- and inter-assay
coefficients of variation
The CV for duplicate punches from 50 fDBS samples was
8.25%, and for duplicate punches from 50 vDBS punches
(A) (B) (C)
FIGURE 1 Passing-Bablok plots showing the relationship between matched, A, fingerprick DBS (fDBS) and plasma osteocalcin
levels, B, venous DBS (vDBS) and plasma osteocalcin levels, and, C, fDBS and vDBS osteocalcin levels. The number of samples analyzed and
the Passing-Bablok regression equations are indicated. Note all osteocalcin values were log10-transformed prior to analyses
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was 8.40%. Note that this value encompasses both well-to-
well variation and position-based differences in analyte
concentrations in a dried blood spot. The inter-assay CV
for one high and one low DBS control was 14.8% (14.6%
for the high control and 15.0% for the low control). Note
that this reflects inter-assay variability, position-based dif-
ferences in analyte concentrations in DBS, and in addition,
variation in the number of freeze-thaw cycles the DBS
TABLE 1 Dilutional linearity of Abcam's osteocalcin ELISA (ab195214) for dried blood spots
Dilution factor
DBS sample Undiluted 2 4 8
1 ng/mL 3.18 1.68 0.77 0.46
% Expected value 100.00 105.45 97.32 116.34
2 ng/mL 3.09 1.61 0.76 nd
% Expected value 100.00 103.95 98.38 nd
3 ng/mL 3.01 1.56 0.83 0.34
% Expected value 100.00 103.29 110.40 89.27
4 ng/mL 2.96 1.35 0.80 < LOD
% Expected value 100.00 91.11 107.68 -
5 ng/mL 2.67 1.14 0.64 < LOD
% Expected value 100.00 85.58 96.22 -
6 ng/mL 3.17 1.44 0.80 0.37
% Expected value 100.00 90.75 100.47 93.15
Note: < LOD indicates a value under the limit of detection (0.34 ng/mL) of the assay. Percentages are indicated in bold.




FIGURE 2 Bland–Altman plots of the difference in, A, plasma and plasma-converted fingerprick DBS (fDBS) osteocalcin values vs
the average of these values, B, plasma and plasma-converted venous DBS (vDBS) osteocalcin values vs the average of these values,
C, unconverted fDBS and vDBS osteocalcin values vs the average of these values, and, D, plasma-converted fDBS and vDBS values vs the
average of these values. Note all osteocalcin values were log10-transformed prior to analyses
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cards were subjected to (the same DBS cards were used for
all plates). For comparison, intra- and inter-assay CVs for
the liquid standards were also calculated, and were 4.8%
and 5.1%, respectively.
3.6 | Limit of detection
The limit of detection of this assay in our laboratory was
0.34 ng/mL, which was slightly higher than that reported
by the manufacturer (0.10 ng/mL), as expected.
3.7 | Analyte stability
Osteocalcin concentrations appeared to be fairly stable in
samples stored at −28C and at room temperature for up to
28 days, with percentage recovery between 80% and 120%
(Figure 3A). In contrast, a steady increase in osteocalcin level
was seen in all samples stored at 37C for longer than 2 days,
implying degradation of osteocalcin into fragments immuno-
reactive with the antibodies provided with the ELISA kit.
The percentage recovery after 3 to 13 freeze-thaw cycles
ranged from 87% to 124%. No clear trend was apparent in all
samples other than an apparent increase in osteocalcin con-
centration in all five samples available for this time point
after 13 freeze thaw cycles relative to the matching samples
that had only undergone a single thaw cycle (Figure 3B).
3.8 | Form of osteocalcin measured
Osteocalcin values for the Anaspec standard were roughly
18% of those of the osteocalcin standard provided with
the kit, indicating that this kit measures total osteocalcin
(both carboxylated and uncarboxylated forms).
TABLE 2 Spike & recovery results
of Abcam's osteocalcin ELISA
(ab195214) for dried blood spots
Measured concentrations (ng/mL)
Neat + 5 ng/mL OC +2.5 ng/mL OC +1.25 ng/mL OC
DBS sample 1 0.34 4.979 2.736 1.511
Expected 4.95 2.848 1.519
Observed/expected (%) 101% 96% 99%
DBS sample 2 0.425 4.94 2.815 1.643
Expected 5.035 2.933 1.604
Observed/expected (%) 98% 96% 102%
(A) (B)
FIGURE 3 A, Stability of osteocalcin concentrations in response to different storage temperatures. VenousDBS (vDBS) samples from six
individuals were stored at−28C, at room temperature (RT, ~22C), and at 37C for 28 days. On day 2, 7, 14, and 28 of storage, sampleswere transferred
to−80C.Osteocalcin concentrations in these sampleswere compared to those in samples stored at−80Cafter collection and thawed only once for this
experiment. The average percentage recovery for all six samples at the various timepoints for the three different storage temperatures is shown. Error
bars are standard errors of themean. Dotted lines indicate 80% and 120% recovery. B, Stability of osteocalcin concentrations in response to different
numbers of freeze-thaw cycles. vDBS samples from six individuals were stored at−28Cand then allowed to thaw at RT for 2 hr 2, 4, 8, or 12 times
(each on separate days) after which theywere returned to the−28C freezer. These sampleswere then thawed one final time to assay osteocalcin
concentrations, for a total number of freeze-thaw cycles of 3, 5, 8, 9, and 13, respectively. Osteocalcin concentrations in these samples were compared to
those in samples stored at−80C after collected and thawed only once for this experiment. Dotted lines indicate 80% and 120% recovery
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4 | DISCUSSION
Here we demonstrated here that a commercial ELISA
developed to measure osteocalcin concentrations in
plasma, serum, and cell culture supernatant can be used
to measure osteocalcin concentrations in DBS based on a
systematic investigation using matched plasma, fDBS,
and vDBS samples. Levels of osteocalcin ranged widely
among individuals from 0.43 to 6.03 ng/mL in fDBS and
64.6 to 619.1 ng/mL in plasma. Previous studies have
reported age- and sex-related differences in osteocalcin
levels (Atalay, Elci, Kayadibi, Onder, & Aka, 2012;
Hannemann et al., 2013; Vanderschueren et al., 1990).
Consistent with these previous studies, we found an
inverse relationship between osteocalcin concentration
and age in all males and females in their second to fifth
decades of life (Bao et al., 2013; Napoli et al., 2013;
Vanderschueren et al., 1990). The lack of a significant rela-
tionship between osteocalcin concentration and age in our
entire female sample was likely because osteocalcin con-
centrations have been shown to be higher in postmeno-
pausal than premenopausal women (Atalay et al., 2012)
and to increase temporarily in females in their sixth decade
of life (Vanderschueren et al., 1990); when we removed
females 50 years and older from our analysis, the expected
inverse relationship with age was observed. Osteocalcin
levels were slightly higher in males than females (mean:
229.3 vs 208.4 ng/mL, respectively) but this difference was
not statistically significant. This is likely due to the inclu-
sion of females in their sixth decade of life in the male/
female comparison as these older females tend to have
higher osteocalcin levels; when females 50 years or older
were removed from this comparison, plasma osteocalcin
values were significantly higher in males than females, as
documented in previous studies (Del Pino et al., 1991;
Napoli et al., 2013; Vanderschueren et al., 1990). The insert
for the Abcam kit reports (graphically) a range of serum
osteocalcin values for 10 male donors of 135 to 280 ng/mL,
with an average value of 268.5 ng/mL. This is similar to the
range of osteocalcin valuesmeasured in the plasma samples
or our male participants (mean: 228.3 ng/mL, range:
105.9-490.8 ng/mL, n = 67). Comparing these values with
reference intervals, however, is not appropriate because of
the variability of platforms and reagents used to measure
osteocalcin, differences in what forms of circulating
osteocalcin are recognized by different antibodies, and the
lack of certified reference standard material for calibration.
Nevertheless, our results affirm that osteocalcin levels mea-
sured using this kit will be internally consistent.
The linear relationship between plasma and DBS
osteocalcin concentrations, and the negligible bias in
plasma-converted DBS vs plasma osteocalcin levels indicate
that there is no systematic difference between osteocalcin
measurements from fingerprick blood and/or that spotted
on DBS cards vs plasma obtained from whole blood. Note,
however, that although there was a linear relationship
between most DBS and plasma samples, not all points fell
exactly on the Passing-Bablok regression lines, suggesting
some variability in DBS vs plasma concentrations of
osteocalcin. The DBS matrix does not interfere with detec-
tion of osteocalcin as indicated by the linearity of dilution
and spike and recovery results. In an earlier study, absence
of dilutional linearity for serum samples (recovery values
ranging from 200% to 700% for 1:8 dilution of serum) was
found for several osteocalcin assays due to the presence
of circulating osteocalcin fragments (Colford, Sailer, &
Langman, 1997). In the current study, the variation in
osteocalcin concentration between punches from duplicate
blood spots run in wells on the same plate of around 8%
was higher than that measured for plasma samples, but this
result is reasonable given that this value encompasses
well-well variation in the osteocalcin concentration in
addition to position-based differences in analyte concen-
trations within a DBS. The inter-assay CV of 14.8% for
high and low DBS controls is at the upper end of the range




important/); as mentioned previously, we attribute this to
the additional variability contributed by punching from
different locations of the same DBS or punching from a
different DBS due to differences in the distribution of
analytes in DBS. Taken together with the low inter-assay
CV obtained for liquid standards of 5.1%, we consider the
reproducibility of this assay to be acceptable. Very few of
the DBS we assayed had osteocalcin levels below the level
of detection we measured for this assay (0.34 ng/mL), indi-
cating that it is feasible to use it for population-level assays
of osteocalcin from DBS, at least in the population our
samples were drawn from (predominantly European
ancestry). Consistent with some other DBS analytes (eg,
TRACP-5b [Eick et al., 2019], immunoreactive trypsinogen
[Li et al., 2006], ferritin and the transferrin receptor [Cook,
Flowers, & Skikne, 1998]), osteocalcin levels were
fairly stable at −28C and at room temperature for up
to 28 days, but appeared to degrade at 37C to produce
fragments that were immunoreactive with the anti-
bodies used by the manufacturer (ie, there was an
apparent increase in osteocalcin levels over time at this
elevated temperature). Osteocalcin levels also tended
to increase with the number of freeze-thaw cycles, but
with variation among samples. After 13 freeze-thaw
cycles, all samples measured had a higher osteocalcin
concentration than at baseline, suggesting that it
would be best to minimize the number of freeze-thaw
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cycles the DBS cards are exposed to prior to assaying
osteocalcin concentration.
The apparent stability of osteocalcin in DBS at room
temperature is noteworthy, as osteocalcin has been
shown to be unstable in vitro both at room temperature
and at 4C (Banfi & Daverio, 1994; Garnero et al., 1994).
This suggests that the filter paper matrix protected
against degradation, as has been demonstrated previously
for other analytes such as TRACP-5b, hydrolases, and
esterases (Eick et al., 2017; Freeman et al., 2018). Finally,
the results we obtained for the carboxylated osteocalcin
standard from Anaspec suggest that the Abcam assay tar-
gets both carboxylated and undercarboxylated forms of full-
length osteocalcin (ie, total osteocalcin; no information is
provided by the kit manufacturer regarding the specificity
of the kit for carboxylated or uncarboxlyated osteocalcin),
indicating that the osteocalcin values obtained using this kit
can be used as a biomarker of bone formation.
This validation study has several limitations. First,
osteocalcin levels in plasma samples were assayed using
the same Abcam kit used to validate the DBS samples,
rather than using a reference measurement. However, no
gold standard method has yet been established for the
measurement of osteocalcin in plasma or serum samples.
This is largely due to the heterogeneity in both carboxyla-
tion levels of circulating osteocalcin and osteocalcin frag-
ment size. Different assays vary in their ability to
recognize the numerous fragments of osteocalcin, and
specificity for one fragment vs another is, in many cases,
not specified or evaluated by the manufacturer. Further-
more, even in cases where the specificity for a particular
osteocalcin fragment or fragments has been reported by
the manufacturer, this has been shown not to necessarily
be accurate (Colford et al., 1997). Another limitation
is that oral contraceptive use, hormone replacement
therapy, diabetes mellitus, and body mass index <18 or
>30 kg/m2 can all affect (decrease) osteocalcin levels,
but were not accounted for in our analyses. There are
also diurnal and seasonal variations in osteocalcin levels,
as well as menstrual cycle variations that may have
affected the measured concentrations of osteocalcin (Lee
et al., 2000). However, concordance between our findings
and those reported in previous studies, such as the nega-
tive correlation between osteocalcin level and age, sug-
gests that the effects of these factors were negligible,
although diurnal variation was somewhat controlled for
by collecting all samples between 5 PM and 9 PM A final
limitation of this study is our focus on validating a com-
mercially available ELISA kit. Commercially available
ELISAs can unfortunately be withdrawn from the market
at any time for a variety of reasons, which largely negates
the substantial amount of work that may have gone into
validating these ELISAs for other types of samples, such
as DBS, than the ELISA was developed for. We originally
sought to develop an in-house ELISA for osteocalcin, and
after several months, we had developed an ELISA that
could reliably measure osteocalcin concentrations in
plasma samples; however, while these values showed a
strong correlation with those measured using a commer-
cially available ELISA, they were uniformly lower,
and when this in-house ELISA was applied to DBS,
osteocalcin concentrations for almost all samples were
below the quantitation limit of the ELISA. We attributed
this lack of sensitivity to the fact that antibody pairs with
sufficiently high binding affinities for detecting low con-
centrations of proteins, as are present in DBS, are not
readily available or are preferably used by their manufac-
turers in commercial ELISA kits and are not available for
purchase. This highlights just one of the many con-
straints faced when developing an in-house ELISA.
5 | CONCLUSIONS
The development of DBS assays for both TRACP-5b, a
marker of bone resorption, and now osteocalcin, a
marker of bone formation, expands the toolkit available
for biological anthropologists, particularly those working
in remote field settings. These assays have potential to
help researchers disentangle the complex parameters
related to bone strength across heterogenous populations
and pursue a more refined investigation of the factors
contributing to and the tradeoffs between bone resorp-
tion and formation across and within life-history stages.
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